Zhejiang Provincial People's Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1978-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
57
Active:0
Completed:2
Trial Phases
5 Phases
Phase 1:8
Phase 2:11
Phase 3:3
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)• Click on a phase to view related trials
Not Applicable
16 (38.1%)Phase 2
11 (26.2%)Phase 1
8 (19.0%)Phase 4
4 (9.5%)Phase 3
3 (7.1%)Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced Thyroid CarcinomaRadioiodine-refractory Differentiated Thyroid Cancer
- Interventions
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT07068542
An Exploratory Study on Gene Methylation Detection of Colorectal Cancer
Recruiting
- Conditions
- CRC (Colorectal Cancer)Adenoma Colon
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 450
- Registration Number
- NCT07033156
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis
Recruiting
- Conditions
- TelitaciceptTreatment ComplianceRheumatoid Arthritis
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06979271
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)
Not Applicable
Not yet recruiting
- Conditions
- Triple-Negative Breast Cancer (TNBC)Neoadjuvant ChemotherapyChemotherapy Effects
- Interventions
- Drug: nab-paclitaxel, carboplatin, and bemotuzumabDrug: epirubicin, cyclophosphamide, and bemotuzumab
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT06975644
Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
Not yet recruiting
- Conditions
- Glioblastoma Multiforme (GBM)
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06939400
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
No news found